Interferon alfa 2b mechanism of action
Common Questions and Answers about Interferon alfa 2b mechanism of action
peg-intron
Probably more important than changing the INF. type would be the addition of one of the new DAA's available(that is if you have Gen type 1)
If you have G 2 or 3 then sometimes changing the type of INF. as well as possibly increasing Riba amt has been tried with some success..
There have been some trials that have experimented with Inci and other DAA's on patients with Geno type 2 ..you may want to look into that or possibly waut until there are more efficacious treatments avail.
http://www.nature.com/eye/journal/v17/n4/full/6700391a.html
"INF-alpha therapy has been known to cause a variety of ocular lesions.1,2 Typical lesions include cottonwool spots and retinal haemorrhages at the posterior fundus, particularly around the optic disc, secondary to retinal ischaemia, which usually appear within 3 months of the onset of therapy.
Steroid pretreatment followed by interferon alfa-2b versus no antiviral drugs increased HBsAg loss at the end of treatments. Active treatments compared to each other did not demonstrate differences post-treatment HBsAg loss or combined outcomes that included loss HBsAg clearance.
ALT normalization was greater after adefovir versus placebo. Lamivudine increased rates of ALT normalization versus placebo at 24 weeks off treatment in HBeAg-negative patients.
Conducted at approximately 40 sites in the United States, the COPILOT study compared weight-based low-dose peginterferon alfa-2b (subcutaneous injection of 0.5 mcg/kg/wk, one-third the dose used in standard HCV combination therapy) versus colchicine (0.6 mg orally, twice daily), an anti-inflammatory and antifibrotic medication, in 555 chronic hepatitis C patients with advanced liver fibrosis who previously failed interferon-based therapies.
[24] This study showed that after 14 days, the combination of pegylated interferon alfa 2b and boceprevir given at a dose of 200 or 400 mg thrice daily was associated with an approximately 2.45 and 2.88-log drop in HCV RNA from baseline.
In addition, several clinical trials assessing the efficacy of boceprevir in a triple combination regimen are being conducted in HCV genotype 1 patients who are interferon-naive and in patients who are considered nonresponders to previous treatment.
But the effect of combination therapy of PegIFN alfa-2b and entecavir (ETV) has never been reported worldwide. We report our experience of the administration of PegIFN alfa-2b in combination with ETV for 48 weeks in 14 CHB patients.
Methods:
In a prospective study at multicenters, patients aged 35 and older with genotype C CHB in Japan received PegIFN alfa-2b (1.
I'm the opposite of Frijole. I did 2b first and failed treatment, 2a the second time. Although successful it was not due to the 2a. But, I found that the side effects were much less than 2b.
Pegylation of interferon alfa-2b produces a product (PegIntron) whose clearance is lower than that of nonpegylated interferon alfa-2b. When compared to INTRON A, PegIntron (1 mcg/kg) has approximately a 7-fold lower mean apparent clearance and a 5-fold greater mean half-life, permitting a reduced dosing frequency. At effective therapeutic doses, PegIntron has approximately 10-fold greater Cmax and 50-fold greater AUC than interferon alfa-2b.
In combination with peginterferon alfa-2b or interferon alfa-2b, for treatment of chronic hepatitis C in patients with compensated liver disease
TABLETS:
In combination with peginterferon alfa-2a:
-Genotypes 1 and 4 in patients less than 75 kg: 1000 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 1 and 4 in patients 75 kg or more: 1200 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 2 and 3: 800 mg/day orally in 2 divided doses for 24 weeks
-Genotypes 5 and 6: Insufficient da
15 mg/kg/day PO or 1000 mg/day PO given in 2 divided doses (in the morning and evening) every day plus interferon alfa-2b 3 million international units/m2 SC 3 times per week. The duration of treatment for genotype 1 is 48 weeks; consider treatment discontinuation if an HCV-RNA value below the level of detection has not been achieved at 24 weeks. The duration of treatment for genotype 2 or 3 is 24 weeks.
Pegylated interferon is a man-made form of interferon, a chemical naturally produced in the body to fight viruses. Interferon helps to stop the hepatitis C virus (HCV) from making new copies of itself. It ramps up the immune system to kill HCV. Pegylated interferon is made with special add-on parts that help the drug stay in the body longer.
Ribavirin is a powerful antiviral drug that helps treat hepatitis C infection.
alfa, beta and gamma. Interferon alfa is used to treat viral hepatitis and some types of cancer.
In the 1980s, researchers were able to create interferon alfa in a laboratory. Hepatitis C is treated with man-made interferon alfa that has a molecule attached to keep it in the body longer and make it more effective, called pegylated interferon.
Recommended
